Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1989 1
1992 4
1993 3
1995 4
1996 3
1997 7
1999 9
2000 4
2001 4
2002 3
2003 7
2004 3
2005 2
2006 4
2007 4
2008 5
2009 1
2010 5
2011 2
2012 5
2013 7
2014 5
2015 4
2016 6
2017 7
2018 5
2019 4
2020 9
2021 7
2022 4
2023 6
2024 8
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Epidermolysis bullosa.
Bardhan A, Bruckner-Tuderman L, Chapple ILC, Fine JD, Harper N, Has C, Magin TM, Marinkovich MP, Marshall JF, McGrath JA, Mellerio JE, Polson R, Heagerty AH. Bardhan A, et al. Among authors: marinkovich mp. Nat Rev Dis Primers. 2020 Sep 24;6(1):78. doi: 10.1038/s41572-020-0210-0. Nat Rev Dis Primers. 2020. PMID: 32973163 Review.
Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility.
Has C, Bauer JW, Bodemer C, Bolling MC, Bruckner-Tuderman L, Diem A, Fine JD, Heagerty A, Hovnanian A, Marinkovich MP, Martinez AE, McGrath JA, Moss C, Murrell DF, Palisson F, Schwieger-Briel A, Sprecher E, Tamai K, Uitto J, Woodley DT, Zambruno G, Mellerio JE. Has C, et al. Among authors: marinkovich mp. Br J Dermatol. 2020 Oct;183(4):614-627. doi: 10.1111/bjd.18921. Epub 2020 Mar 11. Br J Dermatol. 2020. PMID: 32017015 Review.
Diagnosis and management of pemphigus: Recommendations of an international panel of experts.
Murrell DF, Peña S, Joly P, Marinovic B, Hashimoto T, Diaz LA, Sinha AA, Payne AS, Daneshpazhooh M, Eming R, Jonkman MF, Mimouni D, Borradori L, Kim SC, Yamagami J, Lehman JS, Saleh MA, Culton DA, Czernik A, Zone JJ, Fivenson D, Ujiie H, Wozniak K, Akman-Karakaş A, Bernard P, Korman NJ, Caux F, Drenovska K, Prost-Squarcioni C, Vassileva S, Feldman RJ, Cardones AR, Bauer J, Ioannides D, Jedlickova H, Palisson F, Patsatsi A, Uzun S, Yayli S, Zillikens D, Amagai M, Hertl M, Schmidt E, Aoki V, Grando SA, Shimizu H, Baum S, Cianchini G, Feliciani C, Iranzo P, Mascaró JM Jr, Kowalewski C, Hall R, Groves R, Harman KE, Marinkovich MP, Maverakis E, Werth VP. Murrell DF, et al. Among authors: marinkovich mp. J Am Acad Dermatol. 2020 Mar;82(3):575-585.e1. doi: 10.1016/j.jaad.2018.02.021. Epub 2018 Feb 10. J Am Acad Dermatol. 2020. PMID: 29438767 Free PMC article.
Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.
Guide SV, Gonzalez ME, Bağcı IS, Agostini B, Chen H, Feeney G, Steimer M, Kapadia B, Sridhar K, Quesada Sanchez L, Gonzalez F, Van Ligten M, Parry TJ, Chitra S, Kammerman LA, Krishnan S, Marinkovich MP. Guide SV, et al. Among authors: marinkovich mp. N Engl J Med. 2022 Dec 15;387(24):2211-2219. doi: 10.1056/NEJMoa2206663. N Engl J Med. 2022. PMID: 36516090 Clinical Trial.
In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.
Gurevich I, Agarwal P, Zhang P, Dolorito JA, Oliver S, Liu H, Reitze N, Sarma N, Bagci IS, Sridhar K, Kakarla V, Yenamandra VK, O'Malley M, Prisco M, Tufa SF, Keene DR, South AP, Krishnan SM, Marinkovich MP. Gurevich I, et al. Among authors: marinkovich mp. Nat Med. 2022 Apr;28(4):780-788. doi: 10.1038/s41591-022-01737-y. Epub 2022 Mar 28. Nat Med. 2022. PMID: 35347281 Free PMC article. Clinical Trial.
Gene Therapy for Epidermolysis Bullosa.
Marinkovich MP, Tang JY. Marinkovich MP, et al. J Invest Dermatol. 2019 Jun;139(6):1221-1226. doi: 10.1016/j.jid.2018.11.036. Epub 2019 May 5. J Invest Dermatol. 2019. PMID: 31068252 Free article. Review.
Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial.
Tang JY, Marinkovich MP, Wiss K, McCarthy D, Truesdale A, Chiou AS, Eid E, McIntyre JK, Bailey I, Furukawa LK, Gorell ES, Harris N, Khosla RK, Peter Lorenz H, Lu Y, Nazaroff J, Grachev ID, Moore AJ. Tang JY, et al. Among authors: marinkovich mp. Lancet. 2025 Jul 12;406(10499):163-173. doi: 10.1016/S0140-6736(25)00778-0. Epub 2025 Jun 23. Lancet. 2025. PMID: 40570869 Clinical Trial.
Repurposing an epithelial sodium channel inhibitor as a therapy for murine and human skin inflammation.
Winge MCG, Nasrallah M, Jackrazi LV, Guo KQ, Fuhriman JM, Szafran R, Ramanathan M, Gurevich I, Nguyen NT, Siprashvili Z, Inayathullah M, Rajadas J, Porter DF, Khavari PA, Butte AJ, Marinkovich MP. Winge MCG, et al. Among authors: marinkovich mp. Sci Transl Med. 2024 Dec 11;16(777):eade5915. doi: 10.1126/scitranslmed.ade5915. Epub 2024 Dec 11. Sci Transl Med. 2024. PMID: 39661704
Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa.
Marinkovich MP, Paller AS, Guide SV, Gonzalez ME, Lucky AW, Bağcı IS, Agostini B, Fitzgerald K, Chen S, Chen H, Conner MM, Krishnan SM. Marinkovich MP, et al. Am J Clin Dermatol. 2025 Jul;26(4):623-635. doi: 10.1007/s40257-025-00942-y. Epub 2025 Apr 12. Am J Clin Dermatol. 2025. PMID: 40220208 Free PMC article. Clinical Trial.
140 results